StudyRareStudyRare

Intellectual disability and global developmental delay

Log in to star

Last updated Nov 15, 2026

Log in to add personal notes on this page.

Global developmental delay (GDD) is delay in two or more developmental domains (gross motor, fine motor, language, cognition, social) in a child younger than 5, and is a clinical proxy for future intellectual disability. Intellectual disability (ID) is the formal diagnosis after age 5, defined by IQ < 70 plus deficits in adaptive functioning, with onset before 18. This leaf is the general approach to a child with GDD or ID without a diagnosis. Regression (loss of skills) is its own presentation; see developmental regression. Specific syndromes (Down, Williams, etc.) have their own leaves.

Three principles structure the workup:

  1. Yield-driven, not exhaustive. Modern genetic testing has a defined diagnostic hierarchy: exome or genome sequencing as a first- or second-tier test (exome yield 31% in isolated neurodevelopmental disorders and 53% with associated conditions, against 15-20% for microarray), microarray where the sequencing does not cover copy number, fragile X testing in parallel for any boy and most girls (~2% yield), and targeted assays first for clinically recognizable syndromes. A diagnosis matters: it ends the diagnostic odyssey, anchors prognosis, drives surveillance (e.g., Wilms in Beckwith-Wiedemann), reframes recurrence risk, and unlocks family planning options.
  2. Look at the child first; gestalt narrows the panel. If you recognize Down syndrome, Williams syndrome, Angelman syndrome, Prader-Willi syndrome, Smith-Magenis syndrome, or Rett syndrome on inspection, do the targeted test (karyotype + FISH, FISH for 7q11.23, methylation, MECP2) before broad-spectrum testing. CMA still picks most of these up, but turnaround is faster with the targeted assay when the phenotype is clear.
  3. Always think comorbidity and treatability. Hearing loss and vision impairment masquerade as cognitive delay; rule them out at every visit. Treatable inborn errors of metabolism are rare in the NBS era but should be reconsidered in any unscreened immigrant child or regressive course.

Chromosomal and copy-number variants (CMA territory)

Imprinting and methylation disorders

  • Angelman syndrome (15q11-q13 maternal loss): happy demeanor, ataxic gait, seizures, severe language delay.
  • Prader-Willi syndrome (15q11-q13 paternal loss): neonatal hypotonia, later hyperphagia and obesity, hypogonadism, ID.
  • Beckwith-Wiedemann syndrome (11p15.5 imprinting): overgrowth, macroglossia, omphalocele, hypoglycemia, Wilms risk. ID is uncommon; the syndrome belongs in the broader pediatric workup more than the pure ID workup.

Single-gene ID disorders (exome / panel territory)

  • Fragile X syndrome (FMR1 CGG expansion > 200): the most common single-gene cause of inherited ID. Long face, large ears, macroorchidism postpubertally, hand-flapping, social anxiety. Always test boys with unexplained ID; test girls too (skewed X-inactivation can produce a phenotype). Repeat sizing is a separate assay from sequencing panels.
  • Rett syndrome (MECP2): girls, regression-pattern. MECP2 duplication (MECP2 duplication syndrome) affects boys with ID, recurrent infections, spasticity.
  • PTEN hamartoma tumor syndrome: macrocephaly + ID / autism is a high-yield combination for PTEN testing.
  • Tuberous sclerosis complex (TSC1, TSC2): ID, autism, seizures (often infantile spasms), hypopigmented macules.
  • Cornelia de Lange syndrome (NIPBL and others): synophrys, long philtrum, limb anomalies, ID.
  • Rubinstein-Taybi syndrome (CREBBP, EP300): broad thumbs/halluces, distinctive face, ID.
  • Kabuki syndrome (KMT2D, KDM6A): elongated palpebral fissures with everted lower lid, ID, immune, cardiac.
  • Coffin-Siris syndrome (BAF-complex genes including ARID1B): hypoplastic fifth nails / phalanges, coarse face, ID.

ID with autism

Macrocephaly + autism is the classic PTEN combination. Additional ID + ASD genes to keep in mind: CHD8, SCN2A, SHANK3 (Phelan-McDermid), ADNP, DYRK1A, SYNGAP1, ARID1B, GRIN2B, MECP2, UBE3A.

ID with epilepsy / epileptic encephalopathy

  • STXBP1-related disorders: early infantile epileptic encephalopathy, Ohtahara, later Lennox-Gastaut-like phenotypes.
  • CDKL5 deficiency disorder: female-predominant; intractable seizures from the first months of life, cerebral visual impairment, and hand stereotypies that are rarely like Rett hand-wringing.
  • KCNQ2-related disorders: neonatal epileptic encephalopathy; some respond to sodium channel blockers.
  • SCN1A / Dravet syndrome: SCN1A seizure disorders; fever-sensitive seizures, hemiclonic, status; avoid sodium channel blockers.
  • SCN2A, SCN8A, GRIN2A, GNAO1, KCNT1: other epileptic encephalopathy genes.
  • Tuberous sclerosis complex: infantile spasms; vigabatrin is first-line.

ID with metabolic features

Metabolic causes of isolated, non-regressive ID are rare in NBS-era populations but increase in importance for unscreened children. Consider testing in: regression, consanguinity, coarse features, organomegaly, parental concern about decline, episodic encephalopathy, dysmorphism unexplained by CMA / exome.

  • Untreated phenylketonuria: severe ID, fair skin/hair, eczema, musty odor. Preventable with newborn screening + diet.
  • Smith-Lemli-Opitz syndrome (DHCR7): 2-3 toe syndactyly, microcephaly, ID, cholesterol biosynthesis defect.
  • Homocystinuria (CBS): marfanoid habitus, lens dislocation (downward), thromboembolism, ID.
  • Lesch-Nyhan syndrome (HPRT1, X-linked): ID, self-injurious behavior, hyperuricemia, dystonia.
  • Cerebral creatine deficiency syndromes (GAMT, AGAT, SLC6A8): treatable with creatine and supplementation when caught early; CSF/MRS shows absent creatine peak.
  • Untreated congenital hypothyroidism: ID prevented by newborn screening.
  • Macrocephaly + ID or autism → PTEN (single highest-yield association).
  • Boy with ID + large ears + long face + macroorchidism + hand flapping → fragile X.
  • Girl with regression at 6-18 months + hand stereotypies + deceleration of head growth → Rett.
  • Happy demeanor + ataxic gait + seizures + severe language delay → Angelman.
  • Neonatal hypotonia and poor feeding evolving to hyperphagia and obesity → Prader-Willi.
  • Hypercalcemia + supravalvular AS + "cocktail party" personality + stellate iris → Williams.
  • Sleep dysregulation + self-hugging + brachycephaly → Smith-Magenis.
  • ID + 2-3 toe syndactyly + microcephaly → Smith-Lemli-Opitz.
  • ID + downward lens dislocation + marfanoid + thrombosis → homocystinuria (in contrast to Marfan, where lens dislocation is upward and no ID).

The American College of Medical Genetics tiered workup (2021 guideline; older algorithms start with microarray because of the 2010 statement it replaced):

  1. Exome or genome sequencing: first- or second-tier in unexplained GDD/ID with onset before 18 years. Exome yield is 36% across neurodevelopmental disorders, 31% when the disorder is isolated and 53% with associated conditions. Across the guideline's evidence, genome-wide sequencing diagnosed 38% against 21% for standard testing, genome 43% and exome 34%. Sequence the child with both parents (a trio) when possible.
  2. Chromosomal microarray (CMA): before or alongside an exome, which detects copy-number variants only partly; genome sequencing covers array targets. Yield 15-20% in unexplained DD/ID. Still the first-tier test for isolated autism without ID or congenital anomalies, which the 2021 guideline does not cover.
  3. Fragile X (FMR1 CGG repeat sizing): in parallel for boys, and most girls. Exome does not detect repeat expansions, and CMA does not either.
  4. Targeted testing first if a syndrome is recognizable:
    • Karyotype if Down or aneuploidy suspected (CMA misses balanced rearrangements)
    • Methylation studies for Angelman / Prader-Willi / Beckwith-Wiedemann
    • MECP2 sequencing and deletion/duplication for Rett (girls) and MECP2 duplication (boys)
    • FISH or CMA for 7q11.23 (Williams), 17p11.2 (Smith-Magenis), 22q11.2 (DiGeorge / VCFS)
  5. Reanalysis of a negative exome or genome in undiagnosed cases; the best interval is not yet established.
  6. Targeted metabolic workup (when indicated): plasma amino acids, urine organic acids, lactate, ammonia, total homocysteine, copper / ceruloplasmin, acylcarnitines, creatine / GAA, lysosomal enzymes, VLCFAs, urine GAGs. Routine on every child is low yield; targeted to phenotype.
  7. EEG and MRI: EEG if seizures or staring spells. MRI if focal exam, microcephaly, macrocephaly, regression, or unexplained ID after first-pass genetic testing.
  8. Hearing and vision screen. Always. Sensory impairment masquerades as cognitive delay.
  • Fragile X needs its own assay. Repeat sizing is a separate test from exome and sequencing panels. Forgetting to order it is a routine miss in undiagnosed-ID workups.
  • Sequencing and CMA have replaced karyotype as screening tests in ID workups, but karyotype is still right when Down syndrome or balanced rearrangements are suspected. A balanced reciprocal translocation in a parent has huge reproductive-counseling implications and is invisible on CMA.
  • Recurrence risk varies massively by diagnosis. De novo CNV / de novo single-gene: typically < 1% (gonadal mosaicism excluded). Inherited dominant from an affected parent: 50%. AR carrier parents: 25%. X-linked: depends on parental carrier status. Counseling cannot be generic.
  • Reanalyze a negative exome in undiagnosed cases; the best interval is not yet established. The literature evolves; new genes are reported monthly. Reanalysis is one of the highest-yield single interventions in pediatric genetics today.
  • Hypothyroidism and hearing loss are still occasionally missed. Always confirm newborn screening was done and normal; always document hearing and vision at every developmental visit.